ES2543977T3 - Sistema terapéutico transdérmico para la administración del principio activo buprenorfina - Google Patents

Sistema terapéutico transdérmico para la administración del principio activo buprenorfina Download PDF

Info

Publication number
ES2543977T3
ES2543977T3 ES14169050.3T ES14169050T ES2543977T3 ES 2543977 T3 ES2543977 T3 ES 2543977T3 ES 14169050 T ES14169050 T ES 14169050T ES 2543977 T3 ES2543977 T3 ES 2543977T3
Authority
ES
Spain
Prior art keywords
buprenorphine
administration
active substance
therapeutic system
transdermal therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14169050.3T
Other languages
English (en)
Inventor
Thomas Hille
Michael Horstmann
Walter Müller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Application granted granted Critical
Publication of ES2543977T3 publication Critical patent/ES2543977T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sistema terapéutico transdérmico para la administración de buprenorfina a la piel, que comprende una capa dorsal impermeable al principio activo, al menos una capa de matriz autoadhesiva que contiene el principio activo buprenorfina y al menos un ácido carboxílico y dado el caso una capa protectora que es susceptible de ser quitada antes del uso, caracterizado por el hecho de que la capa de matriz está hecha a base de polisiloxanos o poliisobutileno, la buprenorfina está disuelta en el ácido carboxílico o en los ácidos carboxílicos, y esta solución está dispersada en forma de gutículas en la capa de matriz.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES14169050.3T 2006-11-21 2007-11-07 Sistema terapéutico transdérmico para la administración del principio activo buprenorfina Active ES2543977T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006054731A DE102006054731B4 (de) 2006-11-21 2006-11-21 Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054731 2006-11-21

Publications (1)

Publication Number Publication Date
ES2543977T3 true ES2543977T3 (es) 2015-08-26

Family

ID=39326133

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14169050.3T Active ES2543977T3 (es) 2006-11-21 2007-11-07 Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
ES07846537.4T Active ES2581574T3 (es) 2006-11-21 2007-11-07 Sistema terapéutico transdérmico para la administración del principio activo buprenorfina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07846537.4T Active ES2581574T3 (es) 2006-11-21 2007-11-07 Sistema terapéutico transdérmico para la administración del principio activo buprenorfina

Country Status (26)

Country Link
US (5) US9308202B2 (es)
EP (2) EP2769714B1 (es)
JP (2) JP5763296B2 (es)
KR (1) KR101444967B1 (es)
CN (1) CN101528207B (es)
AR (1) AR064268A1 (es)
AU (1) AU2007323387B2 (es)
BR (1) BRPI0719115B8 (es)
CA (1) CA2670290C (es)
CY (2) CY1118154T1 (es)
DE (1) DE102006054731B4 (es)
DK (2) DK2769714T3 (es)
ES (2) ES2543977T3 (es)
HK (2) HK1132921A1 (es)
HU (2) HUE026978T2 (es)
IL (2) IL198743A (es)
IN (1) IN2009CN02662A (es)
MX (2) MX2009005341A (es)
NZ (1) NZ575500A (es)
PL (2) PL2094249T3 (es)
PT (1) PT2769714E (es)
RU (1) RU2484822C2 (es)
SI (2) SI2094249T1 (es)
TW (1) TWI411452B (es)
WO (1) WO2008061625A2 (es)
ZA (1) ZA200901695B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2468274B1 (de) * 2010-12-14 2015-07-01 Acino AG Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
DE102011076653A1 (de) * 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
MX352795B (es) 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2882870C (en) 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014100599A1 (en) * 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103893154A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 包含丁丙诺啡的透皮给药***
WO2014105480A1 (en) * 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
JP5768222B2 (ja) * 2013-03-01 2015-08-26 パナソニックＩｐマネジメント株式会社 転写装置および印刷装置
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
GB2529789A (en) * 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system
ES2703623T3 (es) * 2013-06-28 2019-03-11 Purdue Pharma Lp Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
EP2921184A1 (de) 2014-03-19 2015-09-23 LTS LOHMANN Therapie-Systeme AG Überpflaster mit verbesserter Verträglichkeit und einer langen Haftungsdauer und Verfahren zu seiner Herstellung
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017048595A1 (en) * 2015-09-14 2017-03-23 Amneal Pharmaceuticals Llc Transdermal delivery system
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3678646B1 (en) * 2017-09-04 2021-09-29 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an emulsifier
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
JP2021517572A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
JP7173415B2 (ja) * 2020-08-19 2022-11-16 東洋インキＳｃホールディングス株式会社 貼付剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (es) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19958554C2 (de) * 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
JP4428899B2 (ja) 1999-07-02 2010-03-10 エルテーエス ローマン テラピー−ジステーメ アーゲー ポリシロキサンおよび両親和性溶媒を基にした微小貯蔵所系
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
JP2004525960A (ja) 2001-02-16 2004-08-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
DK1526848T3 (da) * 2002-08-09 2007-10-22 Gruenenthal Gmbh Opiod-receptorantagonister i transdermale systemer med buprenorphin
NZ539936A (en) 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
MX352795B (es) 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
GB2529789A (en) 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system

Also Published As

Publication number Publication date
EP2769714B1 (de) 2015-05-06
SI2769714T1 (sl) 2015-09-30
PL2094249T3 (pl) 2017-11-30
AR064268A1 (es) 2009-03-25
PL2769714T3 (pl) 2015-12-31
BRPI0719115A2 (pt) 2013-12-10
ZA200901695B (en) 2009-12-30
US20180289698A1 (en) 2018-10-11
BRPI0719115B8 (pt) 2021-05-25
US20100119585A1 (en) 2010-05-13
HK1132921A1 (en) 2010-03-12
CY1118154T1 (el) 2017-06-28
TW200836776A (en) 2008-09-16
IN2009CN02662A (es) 2015-08-07
WO2008061625A3 (de) 2008-09-18
IL245290A0 (en) 2016-06-30
CY1117770T1 (el) 2017-05-17
MX2009005341A (es) 2009-06-01
EP2094249B1 (de) 2016-04-13
EP2769714A1 (de) 2014-08-27
HUE026978T2 (en) 2016-08-29
US20160175447A1 (en) 2016-06-23
NZ575500A (en) 2011-12-22
IL198743A (en) 2016-05-31
AU2007323387B2 (en) 2014-01-09
JP5882970B2 (ja) 2016-03-09
BRPI0719115B1 (pt) 2019-04-24
JP2014028844A (ja) 2014-02-13
US20170224676A1 (en) 2017-08-10
WO2008061625A2 (de) 2008-05-29
DE102006054731A1 (de) 2008-05-29
KR101444967B1 (ko) 2014-09-26
CA2670290C (en) 2016-05-31
RU2009123368A (ru) 2010-12-27
MX344241B (es) 2016-12-07
JP2010510259A (ja) 2010-04-02
RU2484822C2 (ru) 2013-06-20
HUE028971T2 (en) 2017-01-30
US20190192506A1 (en) 2019-06-27
DE102006054731B4 (de) 2013-02-28
JP5763296B2 (ja) 2015-08-12
IL198743A0 (en) 2010-02-17
CA2670290A1 (en) 2008-05-29
AU2007323387A1 (en) 2008-05-29
DK2769714T3 (en) 2015-08-03
KR20090082410A (ko) 2009-07-30
CN101528207B (zh) 2012-12-26
HK1200373A1 (en) 2015-08-07
TWI411452B (zh) 2013-10-11
ES2581574T3 (es) 2016-09-06
SI2094249T1 (sl) 2016-07-29
EP2094249A2 (de) 2009-09-02
US9308202B2 (en) 2016-04-12
DK2094249T3 (en) 2016-08-01
PT2769714E (pt) 2015-08-05
CN101528207A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
ES2543977T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
ES2581985T3 (es) Sistema terapéutico transdérmico que contiene norelgestromina para la contracepción y el reemplazo hormonal
ES2524556T3 (es) Composiciones farmacéuticas
PE20151147A1 (es) Sistema de liberacion transdermica
AR089201A1 (es) Sistema de suministro transdermico
CL2016001031A1 (es) Forma de dosificación de liberación inmediata que evita el abuso, que comprende partículas de núcleo recubiertas y una matriz; su uso para preparar un medicamento útil para prevenir, aliviar o aminorar un nivel de dolor y para prevenir el abuso de un fármaco analgésico narcótico, entre otros.
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
NI201500170A (es) Sistema de liberación transdermico
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
AR097045A2 (es) Sistema terapéutico transdérmico
AR048887A1 (es) Aparato y metodo de liberacion transdermica de agentes a base de hormona paratiroidea
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
ES2646737T3 (es) Sistema terapéutico transdérmico para clorhidrato de ácido 5-aminolevulínico
CL2012003229A1 (es) Formulación farmacéutica para aplicación tópica en la piel que comprende una emulsión de aceite en agua y el compuesto (r)-3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrilo, inhibidor de jak1/jak2; método para tratar un trastorno de la piel; y su uso en el tratamiento de un trastorno de la piel.
AR048862A1 (es) Aparatos y metodos para el suministro transdermico de una vacuna antigripal
ECSP099635A (es) Formulaciones líquidas que forman una capa dérmica para la liberación de fármacos a la piel
AR043248A1 (es) Sistema terapeutico transdermico estable a los rayos uv
CL2008003615A1 (es) Composicion farmaceutica transmucosal oral que comprende fenilefrina, o una sal de ella, que esta en forma de tiras, de capa bioadhesiva, de liquido para pulverizar, de pastilla , de gel, de capsulas o de tableta; dispositivo portador.
AR070031A1 (es) Sistemas de administracion transdermicos de droga ketotifen y metodos para el tratamiento de enfermedades oftalmicas
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
AR026040A1 (es) Sistema terapeutico transdermal que contiene clorhidrato de tulobuterol para la administracion del broncodilatador tulobuterol a traves de la piel
AR054012A1 (es) Sistema terapeutico transdermico para la adminstracion de analgesicos
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.